Concepts (114)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 8 | 2020 | 290 | 0.720 |
Why?
|
| Myocardial Infarction | 9 | 2020 | 351 | 0.720 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2012 | 52 | 0.650 |
Why?
|
| Adenocarcinoma | 1 | 2022 | 300 | 0.640 |
Why?
|
| Pancreatic Neoplasms | 3 | 2022 | 548 | 0.630 |
Why?
|
| Thrombectomy | 3 | 2015 | 28 | 0.510 |
Why?
|
| Coronary Thrombosis | 3 | 2015 | 36 | 0.500 |
Why?
|
| Stents | 3 | 2016 | 121 | 0.420 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2020 | 13 | 0.310 |
Why?
|
| Embolism | 1 | 2009 | 14 | 0.310 |
Why?
|
| Registries | 3 | 2016 | 393 | 0.280 |
Why?
|
| ST Elevation Myocardial Infarction | 2 | 2020 | 36 | 0.280 |
Why?
|
| Drug-Eluting Stents | 2 | 2012 | 102 | 0.270 |
Why?
|
| Coronary Disease | 1 | 2007 | 120 | 0.260 |
Why?
|
| Sirolimus | 1 | 2007 | 76 | 0.260 |
Why?
|
| Myocardial Revascularization | 2 | 2018 | 14 | 0.250 |
Why?
|
| Treatment Outcome | 9 | 2020 | 2402 | 0.230 |
Why?
|
| Electrocardiography | 3 | 2015 | 394 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2007 | 534 | 0.200 |
Why?
|
| Cucurbita | 1 | 2022 | 1 | 0.190 |
Why?
|
| Pancreatectomy | 1 | 2022 | 58 | 0.190 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 70 | 0.190 |
Why?
|
| Middle Aged | 12 | 2020 | 7310 | 0.180 |
Why?
|
| Neoplasm Staging | 1 | 2022 | 478 | 0.180 |
Why?
|
| London | 6 | 2020 | 10 | 0.180 |
Why?
|
| Coronary Angiography | 6 | 2015 | 150 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 215 | 0.170 |
Why?
|
| Female | 16 | 2021 | 15472 | 0.160 |
Why?
|
| Hospital Mortality | 7 | 2018 | 157 | 0.160 |
Why?
|
| Mammography | 1 | 2021 | 79 | 0.160 |
Why?
|
| Coronary Vessels | 2 | 2018 | 153 | 0.160 |
Why?
|
| Humans | 16 | 2022 | 28585 | 0.160 |
Why?
|
| Male | 13 | 2020 | 13772 | 0.140 |
Why?
|
| Aged | 8 | 2018 | 5525 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 472 | 0.120 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2012 | 36 | 0.120 |
Why?
|
| Obesity | 1 | 2021 | 675 | 0.110 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2014 | 28 | 0.110 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 218 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 194 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 22 | 0.100 |
Why?
|
| Medical Staff, Hospital | 1 | 2013 | 22 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2018 | 1026 | 0.100 |
Why?
|
| Time Factors | 6 | 2016 | 1600 | 0.100 |
Why?
|
| Cardiology | 1 | 2013 | 48 | 0.100 |
Why?
|
| Acute Coronary Syndrome | 1 | 2013 | 64 | 0.090 |
Why?
|
| Inferior Wall Myocardial Infarction | 1 | 2012 | 1 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 108 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2013 | 1272 | 0.090 |
Why?
|
| Thrombolytic Therapy | 1 | 2012 | 39 | 0.090 |
Why?
|
| United Kingdom | 3 | 2018 | 77 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2013 | 234 | 0.090 |
Why?
|
| Fibrinolytic Agents | 1 | 2012 | 70 | 0.090 |
Why?
|
| Coronary Occlusion | 1 | 2012 | 39 | 0.090 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2010 | 10 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2018 | 893 | 0.080 |
Why?
|
| Coronary Circulation | 1 | 2009 | 30 | 0.080 |
Why?
|
| Prosthesis Design | 1 | 2009 | 88 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 226 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 302 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2020 | 2612 | 0.070 |
Why?
|
| Coronary Artery Bypass | 1 | 2007 | 68 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2015 | 622 | 0.070 |
Why?
|
| Survival Rate | 3 | 2013 | 431 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2016 | 631 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 461 | 0.060 |
Why?
|
| Risk Factors | 3 | 2013 | 2111 | 0.050 |
Why?
|
| Vascular Patency | 2 | 2012 | 44 | 0.050 |
Why?
|
| Plant Breeding | 1 | 2022 | 5 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 145 | 0.050 |
Why?
|
| Propensity Score | 2 | 2013 | 59 | 0.050 |
Why?
|
| Plant Diseases | 1 | 2022 | 39 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 233 | 0.040 |
Why?
|
| Adult | 2 | 2010 | 7922 | 0.040 |
Why?
|
| Stroke | 2 | 2013 | 256 | 0.040 |
Why?
|
| Mortality | 1 | 2018 | 46 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 2045 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2016 | 53 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2016 | 77 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 73 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2015 | 93 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 90 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 288 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 302 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 265 | 0.030 |
Why?
|
| Consultants | 1 | 2013 | 4 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 21 | 0.030 |
Why?
|
| Inservice Training | 1 | 2013 | 9 | 0.030 |
Why?
|
| Operative Time | 1 | 2013 | 41 | 0.020 |
Why?
|
| Emergency Treatment | 1 | 2013 | 26 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2013 | 53 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 203 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 236 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 153 | 0.020 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 47 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 259 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2012 | 5 | 0.020 |
Why?
|
| Suction | 1 | 2012 | 10 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 409 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2012 | 72 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 209 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 568 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 467 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2012 | 273 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 734 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 480 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 190 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 1602 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 1494 | 0.020 |
Why?
|
| Mice | 1 | 2014 | 4735 | 0.010 |
Why?
|
| Animals | 1 | 2014 | 10583 | 0.010 |
Why?
|
| Recurrence | 1 | 1993 | 325 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 415 | 0.010 |
Why?
|